For: | Jaroszewicz J, Rogalska M, Flisiak I, Flisiak R. Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C. World J Gastroenterol 2010; 16(14): 1747-1752 [PMID: 20380007 DOI: 10.3748/wjg.v16.i14.1747] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v16/i14/1747.htm |
Number | Citing Articles |
1 |
KOUICHI HARAGUCHI, HIROFUMI UTO, NOBUHITO OHNOU, MASAHITO TOKUNAGA, MAYUMI TOKUNAGA, ATAE UTSUNOMIYA, SHUICHI HANADA, HIROHITO TSUBOUCHI. Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma. Experimental and Therapeutic Medicine 2012; 4(4): 581 doi: 10.3892/etm.2012.663
|
2 |
Samar F. Darwish, Wesam M. El-Bakly, Reem N. El-Naga, Azza S. Awad, Ebtehal El-Demerdash. Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy. Biochemical Pharmacology 2015; 98(1): 231 doi: 10.1016/j.bcp.2015.09.001
|
3 |
Hakan Çam, Nimet Yılmaz. Serum hepcidin levels are related to serum markers for iron metabolism and fibrosis stage in patients with chronic hepatitis B: A cross-sectional study. Arab Journal of Gastroenterology 2020; 21(2): 85 doi: 10.1016/j.ajg.2020.04.013
|
4 |
Urania Georgopoulou, Alexios Dimitriadis, Pelagia Foka, Eirini Karamichali, Avgi Mamalaki. Hepcidin and the iron enigma in HCV infection. Virulence 2014; 5(4): 465 doi: 10.4161/viru.28508
|
5 |
Jing Wang, Ailian Dong, Gang Liu, Gregory J. Anderson, Tony Y. Hu, Jian Shi, Yulin Hu, Guangjun Nie. Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay. Scientific Reports 2016; 6(1) doi: 10.1038/srep34252
|
6 |
Shintaro Nanba, Fusao Ikeda, Nobuyuki Baba, Koichi Takaguchi, Tomonori Senoh, Takuya Nagano, Hiroyuki Seki, Yasuto Takeuchi, Yuki Moritou, Tetsuya Yasunaka, Hideki Ohnishi, Yasuhiro Miyake, Akinobu Takaki, Kazuhiro Nouso, Yoshiaki Iwasaki, Kazuhide Yamamoto. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C. Journal of Clinical Pathology 2016; 69(3): 226 doi: 10.1136/jclinpath-2015-203215
|
7 |
Motoyuki Kohjima, Tsuyoshi Yoshimoto, Munechika Enjoji, Nobuyoshi Fukushima, Kunitaka Fukuizumi, Tsukasa Nakamura, Miho Kurokawa, Nao Fujimori, Yusuke Sasaki, Yasushi Shimonaka, Yusuke Murata, Susumu Koyama, Ken Kawabe, Kazuhiro Haraguchi, Yorinobu Sumida, Naohiko Harada, Masaki Kato, Kazuhiro Kotoh, Makoto Nakamuta. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World Journal of Gastroenterology 2015; 21(11): 3291-3299 doi: 10.3748/wjg.v21.i11.3291
|
8 |
Maria Paola Simula, Valli De Re. Hepatitis C virus‐induced oxidative stress and mitochondrial dysfunction: A focus on recent advances in proteomics. PROTEOMICS – Clinical Applications 2010; 4(10-11): 782 doi: 10.1002/prca.201000049
|
9 |
Driton Vela. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker. Molecular Medicine 2018; 24(1) doi: 10.1186/s10020-018-0008-7
|